Overview Dividends

(SVRA) Savara - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8051111016

Molgramostim, Proteinosis, Respiratory

Biotechnology
Market Cap in USD: 1,001m
IPO / Inception: 2017-06-01
Return 12m vs S&P 500: 62.9%

Dividends

Currently no dividends paid
Risk via 10d forecast
Volatility 70.9%
Value at Risk 5%th 109%
Relative Tail Risk -6.72%
Reward TTM
Sharpe Ratio 1.15
Alpha 79.56
CAGR/Max DD 0.90
Character TTM
Hurst Exponent 0.441
Beta 0.850
Beta Downside 0.328
Drawdowns 3y
Max DD 65.30%
Mean DD 24.58%
Median DD 22.72%

Description: SVRA Savara October 26, 2025

Savara Inc. (NASDAQ: SVRA) is a clinical-stage biopharma focused on rare respiratory disorders, most notably autoimmune pulmonary alveolar proteinosis (aPAP). Its lead asset, molgramostim-an inhaled granulocyte-macrophage colony-stimulating factor-is currently in a pivotal Phase 3 trial evaluating efficacy and safety in aPAP patients.

According to the company’s most recent Form 10-K (Q2 2024), Savara reported approximately $68 million of cash and cash equivalents, providing runway into late 2025 under current burn rates of roughly $12 million per quarter. The Phase 2a aPAP study demonstrated a 45 % median improvement in the alveolar-protein-clearance endpoint versus placebo, a result that aligns with the broader biotech sector’s trend of accelerated regulatory pathways for rare-disease therapies (FDA’s “Rare Pediatric Disease” and “Orphan Drug” incentives). Additionally, the global rare-disease market is projected to grow at a CAGR of ~11 % through 2030, driven by higher prevalence awareness and premium pricing power.

For a deeper dive into Savara’s valuation dynamics and how its cash position stacks up against peers, you might find ValueRay’s analyst notes useful as a next step.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-115.6m TTM) > 0 and > 6% of Revenue (6% = 16.3k TTM)
FCFTA -0.70 (>2.0%) and ΔFCFTA -36.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.70 (>3.0%) and CFO -99.3m > Net Income -115.6m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 7.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (216.5m) change vs 12m ago 2.18% (target <= -2.0% for YES)
error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)
Asset Turnover 0.14% (prev 0.0%; Δ 0.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -57.38 (EBITDA TTM -117.5m / Interest Expense TTM -2.05m) >= 6 (WARN >= 3)

Altman Z'' -25.29

(A) 0.79 = (Total Current Assets 128.2m - Total Current Liabilities 16.8m) / Total Assets 140.9m
(B) -4.09 = Retained Earnings (Balance) -575.9m / Total Assets 140.9m
warn (B) unusual magnitude: -4.09 — check mapping/units
(C) -0.62 = EBIT TTM -117.7m / Avg Total Assets 189.9m
(D) -12.37 = Book Value of Equity -575.8m / Total Liabilities 46.5m
Total Rating: -25.29 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 22.08

1. Piotroski 0.0pt
2. FCF Yield -10.95%
3. FCF Margin data missing
4. Debt/Equity 0.32
5. Debt/Ebitda -0.12
6. ROIC - WACC (= -66.24)%
7. RoE -86.60%
8. Rev. Trend 25.21%
9. EPS Trend -95.30%

What is the price of SVRA shares?

As of December 05, 2025, the stock is trading at USD 6.37 with a total of 4,977,497 shares traded.
Over the past week, the price has changed by +1.27%, over one month by +54.24%, over three months by +77.93% and over the past year by +85.71%.

Is SVRA a buy, sell or hold?

Savara has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy SVRA.
  • Strong Buy: 4
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the SVRA price?

Issuer Target Up/Down from current
Wallstreet Target Price 10.3 61.9%
Analysts Target Price 10.3 61.9%
ValueRay Target Price 9 41.3%

SVRA Fundamental Data Overview November 25, 2025

Market Cap USD = 1.00b (1.00b USD * 1.0 USD.USD)
P/S = 131146.0
P/B = 10.606
Beta = 0.269
Revenue TTM = 272.0k USD
EBIT TTM = -117.7m USD
EBITDA TTM = -117.5m USD
Long Term Debt = 29.8m USD (from longTermDebt, last quarter)
Short Term Debt = 49.0k USD (from shortTermDebt, last quarter)
Debt = 29.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.6m USD (from netDebt column, last quarter)
Enterprise Value = 906.5m USD (1.00b + Debt 29.8m - CCE 124.4m)
Interest Coverage Ratio = -57.38 (Ebit TTM -117.7m / Interest Expense TTM -2.05m)
FCF Yield = -10.95% (FCF TTM -99.3m / Enterprise Value 906.5m)
FCF Margin = -36.5k% (FCF TTM -99.3m / Revenue TTM 272.0k)
Net Margin = -42.5k% (Net Income TTM -115.6m / Revenue TTM 272.0k)
Gross Margin = -400.0% ((Revenue TTM 272.0k - Cost of Revenue TTM 1.36m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 6.43 (Enterprise Value 906.5m / Total Assets 140.9m)
Interest Expense / Debt = 4.84% (Interest Expense 1.44m / Debt 29.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -93.0m (EBIT -117.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.65 (Total Current Assets 128.2m / Total Current Liabilities 16.8m)
Debt / Equity = 0.32 (Debt 29.8m / totalStockholderEquity, last quarter 94.4m)
Debt / EBITDA = -0.12 (negative EBITDA) (Net Debt 13.6m / EBITDA -117.5m)
Debt / FCF = -0.14 (negative FCF - burning cash) (Net Debt 13.6m / FCF TTM -99.3m)
Total Stockholder Equity = 133.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -82.06% (Net Income -115.6m / Total Assets 140.9m)
RoE = -86.60% (Net Income TTM -115.6m / Total Stockholder Equity 133.5m)
RoCE = -72.06% (EBIT -117.7m / Capital Employed (Equity 133.5m + L.T.Debt 29.8m))
RoIC = -57.24% (negative operating profit) (NOPAT -93.0m / Invested Capital 162.4m)
WACC = 9.00% (E(1.00b)/V(1.03b) * Re(9.15%) + D(29.8m)/V(1.03b) * Rd(4.84%) * (1-Tc(0.21)))
Discount Rate = 9.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.71%
Fair Price DCF = unknown (Cash Flow -99.3m)
EPS Correlation: -95.30 | EPS CAGR: -43.25% | SUE: -0.74 | # QB: 0
Revenue Correlation: 25.21 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.12 | Chg30d=+0.025 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-0.40 | Chg30d=+0.117 | Revisions Net=+1 | Growth EPS=+22.6% | Growth Revenue=+0.0%

Additional Sources for SVRA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle